Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Anttila, Sami A. K.
and
Leinonen, Esa V. J.
2001.
A Review of the Pharmacological and Clinical Profile of Mirtazapine.
CNS Drug Reviews,
Vol. 7,
Issue. 3,
p.
249.
Knapp, Martin
and
Ilson, Sophie
2002.
Economic aspects of depression and its treatment.
Current Opinion in Psychiatry,
Vol. 15,
Issue. 1,
p.
69.
Baker, C. Bruce
Johnsrud, Michael T.
Crismon, M. Lynn
Rosenheck, Robert A.
and
Woods, Scott W.
2003.
Quantitative analysis of sponsorship bias in economic studies of antidepressants.
British Journal of Psychiatry,
Vol. 183,
Issue. 6,
p.
498.
Baker, C. Bruce
Johnsrud, Michael T.
Crismon, M. Lynn
Rosenheck, Robert A.
and
Woods, Scott W.
2003.
Quantitative analysis of sponsorship bias in economic studies of antidepressants.
British Journal of Psychiatry,
Vol. 183,
Issue. 6,
p.
498.
Barrett, Barbara
Byford, Sarah
and
Knapp, Martin
2005.
Evidence of cost-effective treatments for depression: a systematic review.
Journal of Affective Disorders,
Vol. 84,
Issue. 1,
p.
1.
Montgomery, Stuart
Doyle, John J
Stern, Lee
and
McBurney, Christopher R
2005.
Economic Considerations in the Prescribing of Third-Generation Antidepressants.
PharmacoEconomics,
Vol. 23,
Issue. 5,
p.
477.
Wade, Alan G.
Toumi, Idris
and
Hemels, Michiel E. H.
2005.
A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK.
Current Medical Research and Opinion,
Vol. 21,
Issue. 4,
p.
631.
Barbieri, Marco
Drummond, Michael
Willke, Richard
Chancellor, Jeremy
Jolain, Bruno
and
Towse, Adrian
2005.
Variability of Cost-Effectiveness Estimates for Pharmaceuticals in Western Europe: Lessons for Inferring Generalizability.
Value in Health,
Vol. 8,
Issue. 1,
p.
10.
Boulenger, Stephanie
Nixon, John
Drummond, Michael
Ulmann, Philippe
Rice, Stephen
and
de Pouvourville, Gerard
2005.
Can economic evaluations be made more transferable?.
The European Journal of Health Economics,
Vol. 6,
Issue. 4,
p.
334.
J⊘rgensen, Tine Rikke
Stein, Dan J
Despiegel, Nicolas
Drost, Pieter B
Hemels, Michiel EH
and
Baldwin, David S
2006.
Cost-Effectiveness Analysis of Escitalopram Compared with Paroxetine in Treatment of Generalized Anxiety Disorder in the United Kingdom.
Annals of Pharmacotherapy,
Vol. 40,
Issue. 10,
p.
1752.
Simon, Judit
Pilling, Stephen
Burbeck, Rachel
and
Goldberg, David
2006.
Treatment options in moderate and severe depression: decision
analysis supporting a clinical guideline.
British Journal of Psychiatry,
Vol. 189,
Issue. 6,
p.
494.
Croom, Katherine F.
Perry, Caroline M.
and
Plosker, Greg L.
2009.
Mirtazapine.
CNS Drugs,
Vol. 23,
Issue. 5,
p.
427.
Sado, Mitsuhiro
Knapp, Martin
Yamauchi, Keita
Fujisawa, Daisuke
So, Mirai
Nakagawa, Atsuo
Kikuchi, Toshiaki
and
Ono, Yutaka
2009.
Cost-Effectiveness of Combination Therapy Versus Antidepressant Therapy for Management of Depression in Japan.
Australian & New Zealand Journal of Psychiatry,
Vol. 43,
Issue. 6,
p.
539.
Wade, Alan G.
and
Häring, Julia
2010.
A review of the costs associated with depression and treatment noncompliance: the potential benefits of online support.
International Clinical Psychopharmacology,
Vol. 25,
Issue. 5,
p.
288.
Krol, Marieke
Papenburg, Jocé
Koopmanschap, Marc
and
Brouwer, Werner
2011.
Do Productivity Costs Matter?.
PharmacoEconomics,
Vol. 29,
Issue. 7,
p.
601.
Vataire, Anne-Lise
Aballéa, Samuel
Antonanzas, Fernando
Roijen, Leona Hakkaart-van
Lam, Raymond W.
McCrone, Paul
Persson, Ulf
and
Toumi, Mondher
2014.
Core Discrete Event Simulation Model for the Evaluation of Health Care Technologies in Major Depressive Disorder.
Value in Health,
Vol. 17,
Issue. 2,
p.
183.
Comments
No Comments have been published for this article.